Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 789

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 789
---
.

5 Property and equipment, net

| Balance, June 30, 2024      |     | $(thousands) | 674 |   |
|:----------------------------|:----|:-------------|----:|:--|
| Depreciation                |     |              | (17 | ) |
| Balance, September 30, 2024 |     |              | 657 |   |

<div align='center'>F-38</div>

At September 30, 2024, the total capitalized cost of property and equipment was $ 879(June 30, 2024 - $ 879),of which $ 499is not in use. The Company has recognized $ 17(2023 - $ 15) in depreciation expense in the three months ended September 30, 2024, on equipment in use.

6 Accounts payable and accrued liabilities

|                     |     | September 30,2024$(in thousands) |       |     | June 30,2024$(in thousands) |       |
| Trade payables      |     |                                  | 1,871 |     |                             | 1,464 |
| Accrued liabilities |     |                                  |   336 |     |                             |   743 |
| Balance             |     |                                  | 2,207 |     |                             | 2,207 |

7 Related party transactions Valent Technologies, LLC Agreements On November 20, 2023, Dr. Brown was terminated from his position as the Company’s Chief Scientific Officer as a result of cost-cutting measures adopted by the Company; he remains a consultant to the Company. Dr. Brown is a principal of Valent Technologies, LLC (“Valent”) and as a result Valent is a related party to the Company. On September 12, 2010, the Company entered into a Patent Assignment Agreement (the “Valent Assignment Agreement”) with Valent pursuant to which Valent transferred to the Company all its right, title and interest in, and to, the patents for VAL-083owned by Valent. The Company now owns all rights and title to VAL-083and is responsible for further development and commercialization. In accordance with the terms of the Valent Assignment Agreement, Valent is entitled to receive a future royalty on all revenues derived from the development and commercialization of VAL-083.In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent’s subsequent development of VAL-083depending on the development milestones the Company has